Solid Tumor Therapeutics Market Size and Forecast 2035
The global solid tumor therapeutics market reached USD 226.67 billion in 2025 and is forecast to reach USD 475.93 billion by 2035, expanding at a 7.7% CAGR. The market stood at USD 210.46 billion in 2024.
The disease burden supports sustained treatment demand. IARC estimates 20.6 million new cancer cases and 9.8 million cancer deaths worldwide in 2024. Lung cancer accounted for 12.8% of new cases, female breast cancer 11.8%, colorectal cancer 9.9%, prostate cancer 7.5%, and stomach cancer 4.8%. Global cancer incidence is projected to reach 34.4 million cases by 2050.
Commercial oncology revenue is increasingly concentrated in high-value targeted and immune therapies. Merck reported USD 31.68 billion in 2025 Keytruda and Keytruda Qlex sales, while Bristol Myers Squibb reported USD 10 billion in Opdivo revenue. Novartis reported USD 4.78 billion from Kisqali and USD 1.99 billion from Pluvicto during 2025.
Solid Tumor Therapeutics Market Highlights
- 2025 Market Size: USD 226.67 Billion
- 2035 Market Size: USD 475.93 Billion
- CAGR, 2026-2035: 7.7%
- Largest Region: North America
- Fastest-Growing Region: Asia-Pacific
- Largest Cancer Segment: Lung Cancer
- Leading Treatment Platforms: Targeted Therapy and Immunotherapy
- Key Growth Areas: ADCs, tumor-agnostic therapy, precision biomarkers, perioperative immunotherapy, radioligand therapy, protein degraders, TIL therapy and molecular residual disease-guided treatment.
Solid Tumor Therapeutics Market Definition
Solid tumor therapeutics include systemic anticancer medicines and advanced cellular or targeted treatments used against cancers arising in organs and tissues rather than hematologic malignancies.
The market covers lung, breast, prostate, colorectal, ovarian, endometrial, cervical, renal, bladder, gastric, pancreatic, liver, melanoma, head and neck and other solid tumors.
Treatment selection increasingly depends on both tumor origin and molecular characteristics such as HER2, EGFR, ALK, ROS1, RET, KRAS, BRAF, BRCA/HRD, PD-L1, MSI/MMR, TROP2, FRα, Nectin-4, CLDN18.2, MET, ESR1, PTEN and NRG1.
FDA's recent approval activity demonstrates this shift. July 2026 approvals included treatments selected by ROS1, RET fusion, PIK3CA status, and PTEN status, while other 2026 approvals use HER2, PD-L1, ESR1, NRG1, and molecular residual disease to direct therapy.
Key Takeaways
- Checkpoint inhibition remains the largest individual commercial force in solid tumor oncology. Keytruda and Keytruda Qlex generated USD 31.68 billion in 2025, while Opdivo generated USD 10 billion.
- ADCs are moving from late-line metastatic treatment into first-line, neoadjuvant, and adjuvant therapy. Enhertu entered early HER2-positive breast cancer in May 2026, while Padcev-Keytruda expanded into perioperative muscle-invasive bladder cancer.
- Tumor-agnostic treatment is becoming a mainstream precision-oncology strategy. Enhertu treats previously treated HER2-positive solid tumors regardless of the organ of origin, while selpercatinib received traditional approval for RET fusion-positive solid tumors in July 2026.
- Molecular residual disease is beginning to determine adjuvant drug selection. FDA approved atezolizumab in May 2026 for post-cystectomy muscle-invasive bladder cancer with circulating tumor DNA-defined residual disease.
- New drug modalities are entering established solid tumor markets. TIL therapy, oncolytic viruses, targeted protein degraders, and radioligand therapy now sit alongside checkpoint inhibitors, TKIs, and ADCs.
- Subcutaneous checkpoint inhibitors can change treatment delivery economics. Keytruda Qlex and Opdivo Qvantig extend major PD-1 franchises from prolonged IV infusion toward subcutaneous administration.
- Biomarker testing is becoming part of the therapeutic infrastructure. Several recent FDA approvals require companion or authorized testing for HER2, MET, PD-L1, RET, ESR1, PTEN, ROS1, or ctDNA MRD before therapy is selected.
Immunotherapy Remains a Core Solid Tumor Revenue Engine
Immune checkpoint inhibition has transformed the treatment of lung, melanoma, renal, bladder, colorectal, gastric, esophageal, liver, head and neck, breast and gynecological cancers.
Keytruda illustrates the scale of this shift. Merck reported USD 31.68 billion in Keytruda and Keytruda Qlex sales during 2025, representing 7% annual growth.
Bristol Myers Squibb reported USD 10 billion in worldwide Opdivo revenue during 2025, while the company's immuno-oncology portfolio continued to expand through Yervoy, Opdualag, and the subcutaneous Opdivo Qvantig formulation.
Roche's Tecentriq generated CHF 3.57 billion in 2025, while Roche's total oncology sales reached CHF 15.32 billion.
Checkpoint therapy continues to move earlier in disease. Recent approvals now span neoadjuvant, perioperative, and adjuvant treatment in solid tumors rather than concentrating exclusively on unresectable or metastatic cancer.
Subcutaneous Immunotherapy Changes Treatment Delivery
Subcutaneous formulations reduce administration time and can shift treatment away from prolonged IV infusion.
FDA approved Keytruda Qlex in September 2025 across solid tumor indications approved for intravenous pembrolizumab in adults and eligible pediatric patients aged 12 and older. In the supporting NSCLC study, confirmed response rates were 45% for subcutaneous treatment and 42% for IV pembrolizumab, with comparable drug exposure.
FDA approved Opdivo Qvantig in December 2024 across a broad group of nivolumab solid tumor indications, including renal, melanoma, lung, head and neck, bladder, colorectal, liver, gastric and esophageal cancers.
Subcutaneous delivery gives major immunotherapy franchises a route to retain treatment convenience as biosimilar competition and oncology-center capacity become more important.
ADCs Are Moving Into Earlier Treatment
Antibody-drug conjugates have become one of the fastest-expanding treatment platforms in solid tumors.
HER2-directed Enhertu has progressed from metastatic breast cancer into lung, gastric, pan-tumor, and early-stage breast cancer treatment.
FDA approved Enhertu in April 2024 for previously treated HER2-positive unresectable or metastatic solid tumors. In DESTINY-PanTumor02, the objective response rate reached 51.4%, establishing a tumor-agnostic ADC pathway.
The franchise moved much earlier in May 2026 when FDA approved Enhertu for neoadjuvant Stage II-III HER2-positive breast cancer and for adjuvant treatment of residual invasive HER2-positive disease after neoadjuvant treatment.
TROP2 ADC competition is also accelerating.
FDA approved Datroway in May 2026 for unresectable or metastatic triple-negative breast cancer in patients who are not candidates for PD-1/PD-L1 therapy. TROPION-Breast02 produced a median PFS of 10.8 months versus 5.6 months with chemotherapy and a 64% response rate versus 30%.
On June 24, 2026, FDA expanded Trodelvy into first-line TNBC, including monotherapy and a pembrolizumab-containing strategy.
Padcev-Keytruda Establishes the ADC-Immunotherapy Model
Nectin-4-directed Padcev and PD-1 inhibitor Keytruda provide the strongest commercial validation for an ADC-checkpoint combination.
The combination progressed from advanced urothelial cancer into curative-intent treatment.
FDA expanded Padcev plus pembrolizumab on July 10, 2026 for neoadjuvant treatment followed by adjuvant therapy after cystectomy in adults with muscle-invasive bladder cancer, extending treatment from cisplatin-ineligible patients to all eligible cystectomy candidates.
This development is important across the ADC market because it demonstrates that an ADC can become part of a perioperative treatment program rather than remain confined to metastatic therapy.
Precision Oncology Is Moving Beyond Common Driver Mutations
EGFR, ALK and BRAF established the targeted-treatment model in solid tumors. The addressable biomarker map now includes much rarer molecular alterations.
FDA granted traditional approval in July 2026 to selpercatinib for RET fusion-positive locally advanced or metastatic solid tumors in adults and children aged two years and older who meet treatment criteria.
Zenocutuzumab established NRG1 fusion as another actionable target. Its initial approval covered NRG1-positive NSCLC and pancreatic adenocarcinoma, and FDA added advanced NRG1-positive cholangiocarcinoma in May 2026.
FDA approved Emrelis/telisotuzumab vedotin in May 2025 for previously treated non-squamous NSCLC with high c-Met protein expression. The indication requires strong c-Met expression in at least 50% of tumor cells using an approved companion diagnostic.
These approvals increase the value of broad genomic and protein-expression profiling because actionable populations can now be defined by mutations, fusions or quantitative antigen expression.
KRAS-Selected Therapy Expands Beyond Lung Cancer
KRAS has shifted from a historically difficult oncology target to a treatment-selection biomarker.
FDA approved the combination of avutometinib and defactinib in May 2025 for adults with KRAS-mutated recurrent low-grade serous ovarian cancer following previous systemic treatment.
RAMP-201 produced a 44% confirmed response rate, with responses lasting from 3.3 months to more than 31 months in the reported dataset.
The approval demonstrates that precision treatment based on KRAS biology can extend beyond the established KRAS G12C lung and colorectal market into rare gynecological cancer subtypes.
CLDN18.2 Creates a New Gastrointestinal Cancer Segment
CLDN18.2 has become a commercially validated biomarker in gastric and gastroesophageal junction cancer.
FDA approved Vyloy/zolbetuximab with chemotherapy for first-line treatment of CLDN18.2-positive, HER2-negative locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma.
SPOTLIGHT reduced the risk of progression or death by 25%, while GLOW reduced the risk by 31%.
The approval expands precision gastrointestinal oncology beyond HER2, MSI/MMR and PD-L1.
Protein Degradation Enters Solid Tumor Therapy
Targeted protein degradation has moved from pipeline concept into an approved solid tumor modality.
FDA approved vepdegestrant in May 2026 for ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer after progression on endocrine therapy. The drug is a heterobifunctional protein degrader targeting the estrogen receptor.
The commercial significance extends beyond breast cancer.
Protein degradation can potentially address targets that are difficult to inhibit conventionally and may create another broad drug-development platform alongside kinase inhibition, monoclonal antibodies and ADCs.
Radioligand Therapy Expands Into Earlier Prostate Cancer
Radioligand therapy is becoming a larger component of precision solid tumor treatment.
Novartis reported USD 1.99 billion in Pluvicto sales during 2025, representing 43% annual growth.
On July 31, 2026, FDA approved Pluvicto in combination with androgen receptor pathway inhibitor therapy for adults with PSMA-positive metastatic androgen pathway modulation-naïve or sensitive prostate cancer.
The earlier indication substantially increases the addressable population relative to heavily pretreated metastatic castration-resistant disease.
Cellular Therapy Is Breaking Into Solid Tumors
Solid tumors have historically been difficult targets for cellular therapy because of tumor heterogeneity, immune suppression and poor cell trafficking.
FDA approval of Amtagvi/lifileucel in February 2024 created the first cellular therapy for unresectable or metastatic melanoma.
The TIL product produced a 31.5% response rate in the efficacy population after prior PD-1 therapy and, where relevant, BRAF-directed therapy.
NCI reported further progress in 2026 using selected TIL therapy with pembrolizumab in heavily pretreated gastrointestinal cancers. Objective responses occurred in 23.5% of patients receiving selected TILs plus pembrolizumab, compared with 7.7% receiving selected TIL therapy without pembrolizumab. Responses occurred across colorectal, pancreatic and biliary cancers.
The data support expansion of cell therapy beyond melanoma if manufacturing, antigen selection and tumor trafficking continue improving.
Oncolytic Virus Therapy Adds Another Immune Modality
On August 6, 2026, FDA granted accelerated approval to vusolimogene oderparepvec-wtpg plus nivolumab for adults with unresectable advanced cutaneous melanoma progressing after a PD-1-based regimen.
The product is a genetically modified oncolytic viral therapy and represents another mechanism for addressing checkpoint-refractory tumors.
Oncolytic therapy can complement immune checkpoint blockade by generating tumor-cell destruction and local immune activation inside the tumor microenvironment.
Molecular Residual Disease Enters Solid Tumor Drug Selection
Circulating tumor DNA is moving from prognostic research toward direct treatment selection.
On May 15, 2026, FDA approved Tecentriq and Tecentriq Hybreza as adjuvant treatment after cystectomy for muscle-invasive bladder cancer with ctDNA-defined molecular residual disease.
This represents a major change in adjuvant oncology.
Traditional treatment decisions rely on stage, pathology and clinicopathologic risk. Molecular residual disease can identify patients who still carry detectable cancer-derived DNA after curative-intent surgery.
The resulting market opportunity extends beyond drug sales into high-sensitivity liquid biopsy, longitudinal molecular monitoring and treatment-response testing.
Solid Tumor Therapeutics Market Scope
| Metrics | Details |
| Historical Years | 2023-2024 |
| Base Year | 2025 |
| Market Size 2025 | USD 226.67 Billion |
| Forecast Period | 2026-2035 |
| Market Size 2035 | USD 475.93 Billion |
| CAGR | 7.70% |
| Largest Region | North America |
| Fastest-Growing Region | Asia-Pacific |
| Cancer Type | Lung, Breast, Prostate, Colorectal, Gynecological, Renal & Urothelial, Gastrointestinal, Others |
| Therapy Type | Targeted Therapy, Immunotherapy, Chemotherapy, Endocrine Therapy, ADCs, Advanced Therapies |
| Biomarkers | HER2, PD-L1, EGFR, ALK, ROS1, RET, KRAS, BRAF, BRCA/HRD, MSI/MMR, TROP2, FR伪, Nectin-4, MET, CLDN18.2, ESR1, PTEN, NRG1 |
| Treatment Setting | Neoadjuvant, Adjuvant, First-Line Metastatic, Later-Line Metastatic |
| End Users | Hospitals, Comprehensive Cancer Centers, Specialty Oncology Clinics, Cellular Therapy Centers |
| North America | U.S., Canada, Mexico |
| Europe | Germany, UK, France, Italy, Spain, Rest of Europe |
| Asia-Pacific | China, Japan, India, South Korea, Australia, Rest of Asia-Pacific |
| Latin America | Brazil, Argentina, Mexico, Rest of Latin America |
| Middle East & Africa | Saudi Arabia, UAE, Israel, South Africa, Rest of MEA |
| Revenue Units | USD Billion |
Therapy Segment Analysis
Targeted & Precision Therapy Leads with 36.5%
Targeted and precision therapies hold 36.5% of 2025 revenue, equal to USD 82.74 billion.
The category includes kinase inhibitors, CDK4/6 inhibitors, PARP inhibitors, anti-HER2 medicines, anti-VEGF therapies, precision antibodies and other molecularly selected treatments.
Commercial performance across several targeted franchises confirms the scale of the segment. Novartis reported USD 4.78 billion in Kisqali sales, USD 2.22 billion from Tafinlar-Mekinist and USD 1.99 billion from Pluvicto during 2025.
Targeted therapy growth increasingly comes from smaller biomarker populations rather than one broad histology. RET, ROS1, MET, NRG1, ESR1, PTEN and CLDN18.2 now define separate treatment pathways.
Immunotherapy Holds 27.5%
Immunotherapy accounts for 27.5% of the market, equal to USD 62.33 billion.
Checkpoint inhibitors dominate the segment.
Keytruda alone generated USD 31.68 billion in 2025, while Opdivo generated USD 10 billion and Tecentriq CHF 3.57 billion.
Growth increasingly comes from early-stage, perioperative and biomarker-selected indications rather than metastatic expansion alone.
Chemotherapy Holds 15%
Chemotherapy accounts for 15% of 2025 revenue, equal to USD 340 billion.
Platinum drugs, taxanes, fluoropyrimidines, gemcitabine, anthracyclines, irinotecan and other cytotoxic medicines remain essential across lung, breast, colorectal, ovarian, gastric, pancreatic and other cancers.
Their commercial role is changing from standalone treatment toward combination backbones for immunotherapy, ADCs and targeted medicines.
The pembrolizumab ovarian approval, for example, combines checkpoint inhibition with paclitaxel with or without bevacizumab.
Endocrine Therapy Holds 12%
Endocrine and hormone-pathway therapies account for 12%, equal to USD 27.20 billion.
The segment is concentrated in breast and prostate cancers.
Modern endocrine treatment increasingly combines hormone suppression with CDK4/6, PI3K/AKT, PARP or other targeted therapies.
FDA's July 2026 breast cancer approval of gedatolisib with fulvestrant, with or without palbociclib, and its June 2026 approval of capivasertib with abiraterone in PTEN-deficient prostate cancer demonstrate this convergence of endocrine and biomarker-targeted therapy.
Antibody-Drug Conjugates Hold 6%
ADCs generate 6% of 2025 market revenue, equal to USD 13.60 billion.
Commercial products include Enhertu, Padcev, Trodelvy, Elahere, Datroway, Kadcyla, Tivdak and Emrelis.
AbbVie reported USD 690 million in 2025 Elahere revenue, up strongly as FRα-directed treatment expanded in ovarian cancer.
The largest growth opportunity is earlier-line use. Enhertu, Padcev and Trodelvy now demonstrate movement into first-line, neoadjuvant or adjuvant solid tumor treatment.
Cancer Type Segment Analysis
Lung Cancer Leads with 24%
Lung cancer generates 24% of 2025 solid tumor therapeutics revenue, equal to USD 54.40 billion.
Lung cancer was the world's most frequently diagnosed cancer in 2024, with 2.6 million new cases, and the leading cause of cancer death with 1.9 million deaths.
Treatment spans PD-1/PD-L1 immunotherapy, EGFR, ALK, ROS1, RET, BRAF, MET and KRAS targeting, chemotherapy and ADCs.
The 2025 Emrelis approval added c-Met protein overexpression as a treatment route, while the July 2026 approval of zidesamtinib expanded ROS1-positive NSCLC therapy.
Breast Cancer Holds 23%
Breast cancer accounts for 23%, equal to USD 52.13 billion.
Female breast cancer represented 11.8% of worldwide new cancer diagnoses in 2024, making it the second most frequently diagnosed malignancy.
The commercial market spans endocrine therapy, CDK4/6 inhibitors, HER2 antibodies, ADCs, PARP inhibitors, PI3K/AKT pathway treatment and immunotherapy.
Kisqali generated USD 4.78 billion in 2025, while ADC competition expanded rapidly through Enhertu, Trodelvy and Datroway.
Prostate Cancer Holds 15.5%
Prostate cancer generates 15.5% of market revenue, equal to USD 35.14 billion.
The market is driven by androgen receptor pathway inhibitors, androgen deprivation therapy, chemotherapy, PARP inhibitors and PSMA-directed radioligand therapy.
Pluvicto's July 2026 expansion into metastatic hormone-sensitive disease increases radioligand therapy's addressable population, while PTEN-directed capivasertib adds another biomarker-selected treatment route.
Colorectal Cancer Holds 10.5%
Colorectal cancer accounts for 10.5%, equal to USD 23.80 billion.
IARC estimates colorectal cancer represented 9.9% of new cancer diagnoses worldwide in 2024 and 9.4% of cancer deaths.
The treatment market includes chemotherapy, anti-VEGF therapy, EGFR-directed antibodies, BRAF/KRAS-targeted treatment and MSI/MMR-directed immunotherapy.
FDA approved nivolumab plus ipilimumab in April 2025 for unresectable or metastatic MSI-H/dMMR colorectal cancer. In first-line disease, median PFS had not been reached with immunotherapy versus 5.8 months with chemotherapy in the reported analysis.
Gynecological Cancers Hold 9%
Gynecological solid tumors generate 9%, equal to USD 20.40 billion.
Ovarian and endometrial cancers lead treatment spending, supported by checkpoint inhibitors, PARP inhibitors, ADCs and targeted molecular therapies.
FDA activity in 2025-2026 included KRAS-directed Avmapki/Fakzynja, PD-L1-selected pembrolizumab, relacorilant, Datroway-related women's cancer expansion and continued FRα-directed Elahere commercialization.
Renal and Urothelial Cancers Hold 7%
Renal and urothelial cancers account for 7%, equal to USD 15.87 billion.
Checkpoint inhibitors, VEGF-directed medicines, HIF-2α therapy and ADCs are central growth platforms.
FDA approved belzutifan plus pembrolizumab for adjuvant clear-cell renal carcinoma in June 2026, while Padcev-Keytruda moved into perioperative muscle-invasive bladder cancer in July.
Gastrointestinal Solid Tumors Hold 6%
Gastric, gastroesophageal, pancreatic, liver and biliary cancers account for 6%, equal to USD 13.60 billion.
Treatment is becoming increasingly biomarker-routed through HER2, MSI/MMR, PD-L1, CLDN18.2 and NRG1.
Vyloy established CLDN18.2-directed treatment in first-line gastric/GEJ cancer, while Bizengri expanded NRG1-directed therapy into pancreatic, lung and cholangiocarcinoma populations.
Solid Tumor Therapeutics Geographical Analysis
North America Leads with 41%
North America accounts for 41% of 2025 global revenue, equal to USD 92.93 billion.
The United States drives the region through high oncology spending, rapid FDA approvals, widespread biomarker testing and early adoption of immunotherapy, targeted medicines, ADCs, radioligands and cellular therapy.
The breadth of U.S. innovation is visible in the 2026 FDA calendar alone, which includes new approvals or expansions across melanoma, prostate, breast, lung, bladder, kidney, ovarian and molecularly defined pan-tumor disease.
Canada contributes through publicly funded oncology systems and broad specialty-drug access, while Mexico represents a smaller but expanding private and institutional oncology market.
Europe Holds 25.8%
Europe generates 25.8% of global revenue, equal to USD 58.48 billion.
Germany, the UK, France, Italy and Spain are the largest pharmaceutical markets in the region.
European solid tumor treatment closely follows global shifts toward checkpoint inhibition, precision medicine and ADCs, but country-specific health technology assessment and reimbursement timelines determine the speed of uptake.
The region also holds strong radioligand, biologics and diagnostic capabilities, supporting expanding biomarker-directed treatment.
Asia-Pacific Holds 24.8% and Records the Fastest Growth
Asia-Pacific accounts for 24.8%, equal to USD 56.22 billion.
The region combines high cancer incidence with rapidly expanding precision oncology access.
China, Japan and South Korea have become important drug-development and commercialization centers, while India is expanding specialist cancer infrastructure and access to biologics.
Asia's growth potential is strengthened by rising cancer diagnosis, broader genomic testing, local oncology innovation and the introduction of global targeted and immune therapies into earlier treatment lines.
Latin America Holds 4.6%
Latin America represents 4.6% of 2025 market revenue, equal to USD 10.43 billion.
Brazil leads regional oncology spending, followed by Mexico, Argentina and other large urban markets.
Checkpoint inhibitors and precision oncology are expanding, but access differs sharply between private systems, major public cancer centers and lower-resource settings.
Competitive Landscape
Merck & Co.
Merck holds the largest individual solid tumor franchise through Keytruda.
Keytruda and Keytruda Qlex generated USD 31.68 billion in 2025, increasing 7%.
The franchise spans multiple tumor types and is now expanding through subcutaneous administration, ADC combinations and early-stage treatment.
Keytruda Qlex became available across eligible solid tumor pembrolizumab indications in September 2025.
Merck's solid tumor strategy also includes Welireg and multiple precision-oncology combinations.
AstraZeneca and Daiichi Sankyo
AstraZeneca and Daiichi Sankyo hold one of the strongest ADC positions through Enhertu and Datroway.
Enhertu now spans metastatic breast, lung, gastric, pan-tumor HER2-positive disease and early-stage HER2-positive breast cancer.
Datroway expanded into TNBC in May 2026 after earlier breast and lung cancer approvals.
AstraZeneca additionally competes through Tagrisso, Imfinzi, Lynparza, Truqap and other precision and immuno-oncology products.
Bristol Myers Squibb
BMS recorded USD 10 billion in Opdivo sales during 2025.
The company competes across PD-1, CTLA-4 and LAG-3 pathways through Opdivo, Yervoy and Opdualag.
Opdivo Qvantig provides a subcutaneous version of nivolumab across multiple adult solid tumor indications.
Roche
Roche's solid tumor portfolio spans Tecentriq, Phesgo, Perjeta, Kadcyla, Alecensa, Avastin and Herceptin.
Roche reported CHF 15.32 billion in oncology sales during 2025, including CHF 3.57 billion from Tecentriq, CHF 2.97 billion from Perjeta, CHF 2.44 billion from Phesgo and CHF 23 billion from Kadcyla.
Roche's diagnostics business also strengthens its position where companion testing determines treatment eligibility.
Novartis
Novartis holds strong positions in breast cancer, melanoma and radioligand therapy.
Kisqali generated USD 4.78 billion in 2025, Tafinlar-Mekinist USD 2.22 billion and Pluvicto USD 1.99 billion.
Pluvicto's July 2026 earlier-line prostate cancer expansion provides one of the largest radioligand growth opportunities in solid tumor oncology.
AbbVie
AbbVie reported USD 6.66 billion in total oncology revenue in 2025 and USD 690 million from Elahere.
Its solid tumor portfolio expanded with Emrelis, a c-Met ADC approved in NSCLC in May 2025.
The combination of FRα and c-Met ADCs gives AbbVie two distinct biomarker-selected solid tumor platforms.
Pfizer and Astellas
Pfizer and Astellas compete through Padcev/enfortumab vedotin, which targets Nectin-4.
The Padcev-Keytruda combination now covers advanced urothelial cancer and perioperative muscle-invasive bladder cancer.
Its movement into curative-intent treatment provides a major growth path for the ADC franchise.
Gilead Sciences
Gilead competes through Trodelvy/sacituzumab govitecan, an established TROP2 ADC.
FDA expanded Trodelvy on June 24, 2026 into first-line triple-negative breast cancer through both monotherapy and pembrolizumab-containing treatment settings.
This creates direct TROP2 competition with Datroway across breast cancer.
Recent Solid Tumor Therapeutics Market Developments
- August 6, 2026: FDA granted accelerated approval to Tudriqev plus nivolumab for PD-1-refractory unresectable advanced cutaneous melanoma, adding an oncolytic viral therapy to the post-checkpoint market.
- July 31, 2026: FDA expanded Pluvicto into PSMA-positive metastatic androgen pathway modulation-naïve or sensitive prostate cancer in combination with an androgen receptor pathway inhibitor.
- July 22, 2026: FDA approved zidesamtinib for previously treated ROS1-positive locally advanced or metastatic NSCLC.
- July 14, 2026: FDA approved gedatolisib-based therapy for HR-positive/HER2-negative advanced breast cancer without a detected PIK3CA mutation and granted traditional approval to selpercatinib for RET fusion-positive solid tumors.
- July 10, 2026: FDA expanded Padcev plus Keytruda into perioperative muscle-invasive bladder cancer for patients undergoing cystectomy regardless of cisplatin eligibility.
- June 24, 2026: FDA approved Trodelvy as monotherapy and with pembrolizumab in first-line TNBC and approved an Ibrance-HER2-endocrine maintenance regimen in HR-positive/HER2-positive metastatic breast cancer.
- June 12, 2026: FDA approved Truqap plus abiraterone and prednisone for PTEN-deficient metastatic prostate cancer and Welireg plus pembrolizumab for adjuvant clear-cell RCC.
- May 22, 2026: FDA approved Datroway for unresectable or metastatic TNBC in patients not eligible for PD-1/PD-L1 inhibitor therapy.
- May 15, 2026: FDA approved Enhertu in two early-stage HER2-positive breast cancer indications and approved Tecentriq for ctDNA MRD-positive muscle-invasive bladder cancer after cystectomy.
- May 8, 2026: FDA approved Bizengri for NRG1 fusion-positive advanced cholangiocarcinoma.
- March 25, 2026: FDA approved Lifyorli/relacorilant plus nab-paclitaxel for platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer after prior bevacizumab.
Strategic Growth Opportunities Through 2035
Earlier-Line ADC Treatment
ADCs are moving from heavily pretreated metastatic populations into first-line and curative-intent treatment.
Enhertu's neoadjuvant and adjuvant approvals, Padcev's perioperative bladder cancer expansion, and Trodelvy's first-line TNBC approval establish this trend across three large franchises.
Earlier treatment increases eligible patient numbers and treatment duration, creating one of the strongest revenue opportunities in solid tumor oncology.
Tumor-Agnostic Targeted Therapy
HER2 and RET demonstrate that treatment can be approved across multiple organs when a target produces sufficient response across different tumor types.
Broad molecular testing therefore becomes necessary even for rare genomic alterations because one test can route patients toward therapies outside traditional organ-specific algorithms.
Molecular Residual Disease
ctDNA-based MRD selection creates a new market between definitive surgery and radiographic relapse.
The Tecentriq bladder cancer approval provides direct regulatory validation of this model.
Future applications can extend into colorectal, lung, breast, and other cancers where postoperative molecular relapse can be detected before visible metastatic disease.
ADC-Immunotherapy Combinations
Padcev-Keytruda and Trodelvy-Keytruda demonstrate the clinical and commercial logic of combining targeted payload delivery with immune activation.
Similar combinations across TROP2, HER2, FRα and newer ADC targets can become major first-line strategies.
Protein Degradation
Vepdegestrant establishes targeted protein degradation as a commercial solid tumor modality.
Expansion into additional hormone receptors, transcriptional regulators, and historically difficult intracellular targets could create a new precision-therapy class.
Radioligand Expansion
Pluvicto's USD 1.99 billion 2025 revenue and earlier-line prostate cancer approval confirm strong demand for radioligand treatment.
Future growth depends on manufacturing capacity, radioisotope availability, nuclear-medicine infrastructure, and new tumor-specific targets beyond PSMA and somatostatin receptors.
Solid Tumor Cell Therapy
Amtagvi established commercial TIL therapy in melanoma, while NCI gastrointestinal cancer results show activity can extend beyond melanoma when tumor-reactive lymphocytes are selected effectively.
Improved manufacturing, reduced lymphodepletion burden, and better tumor-antigen selection can create broader cell-therapy markets in common solid cancers.
Target Audience
Pharmaceutical and biotechnology companies, immuno-oncology developers, ADC companies, targeted-therapy manufacturers, radiopharmaceutical companies, cell-therapy developers, companion-diagnostic companies, genomic-testing laboratories, comprehensive cancer centers, specialty oncology clinics, CROs, healthcare investors, licensing teams and market-access organizations.
